Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1808TiP - Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Small Cell Lung Cancer

Presenters

Giulia Martini

Citation

Annals of Oncology (2020) 31 (suppl_4): S974-S987. 10.1016/annonc/annonc290

Authors

G. Martini1, E. Bria2, C. Gridelli3, M.C. Garassino4, A. Ardizzoni5, F. De Marinis6

Author affiliations

  • 1 Dipartimento Di Medicina Di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Medical Oncology Department, Istituto di Medicina interna e geriatria-Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S., 00168 - Rome/IT
  • 3 Medical Oncology, A.O.S.G. Moscati, 83100 - Avellino/IT
  • 4 Medical Thoracic Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 5 Department Of Experimental, Diagnostic And Specialty Medicine - Dimes, University of Bologna, 40126 - Bologna/IT
  • 6 Medical Thoracic Oncology, IRCCS Istituto Europeo Di Oncologia IEO, 20141 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1808TiP

Background

Despite many attempts to develop effective systemic therapies for ES-SCLC, very little progress has been made in the last several decades. According to the results of the IMpower133 trial (N Engl J Med 2018), the combination of the PD-L1 inhibitor ATZ and Cb-Eto should be currently considered the standard front-line treatment for ES-SCLC. This combination was associated with longer progression free survival (PFS) and overall survival (OS) compared to placebo-Cb-Eto. The median OS at follow-up of 22.9 months confirmed the data of primary analysis with 12.3 months in the ATZ arm vs 10.3 months in the placebo arm (HR, 0.76; 95% CI, 0.60-0.95; P = .0154) (Reck et al. ESMO Congress 2019). The safety profile of ATZ combination has been consistent with the defined toxic effects of the individual agents. Additional studies that evaluate the safety and efficacy also in subsets of patients not included in the pivotal trial can give further support to daily clinical practice.

Trial design

MAURIS is a multi-center, open-label, one arm, phase IIIb trial that evaluate the safety and efficacy of ATZ plus Cb and Eto in patients with newly diagnosed ES- SCLC. Unlike the IMpower133 trial, also patients with ECOG PS2 and untreated asymptomatic brain metastases are eligible for this study. Patients will be addressed to receive chemotherapy plus ATZ 1200 mg every 3 weeks for a total of 4–6 cycles in the induction phase, followed by ATZ maintenance every 3 weeks up to progression, unacceptable toxicity or clinical deterioration. Thoracic consolidation radiotherapy is allowed. Primary endpoints are incidence of serious adverse events (SAEs) related to treatment and incidence of serious and non-serious immune-mediated AEs among patients receiving at least one dose of study therapy. Secondary endpoints include efficacy by RECIST v1.1 (PFS, overall response rate (ORR) and OS. Enrollment is ongoing with 131 out of 150 recruited in 26 Italian centers.

Clinical trial identification

NCT04028050.

Editorial acknowledgement

Legal entity responsible for the study

Roche.

Funding

Roche.

Disclosure

G. Martini: Advisory/Consultancy, Research grant/Funding (self): Merck; Advisory/Consultancy, Research grant/Funding (self): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Amgen; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Servier; Research grant/Funding (institution): Ipsen. E. Bria: Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Celgene; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Helsinn; Advisory/Consultancy: Eli-Lilly; Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Research grant/Funding (institution): AIRC, IASLC, Cariverona. C. Gridelli: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca, BMS, Merck, Roche. M.C. Garassino: Advisory/Consultancy: AstraZeneca, BMS, Merck, Roche, Sharp & Dohme, Boehringer Ingelheim, Eli Lilly. A. Ardizzoni: Honoraria (self): Eli Lilly, Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: BMS; Advisory/Consultancy: MSD, AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Roche; Research grant/Funding (institution): Celgene. F. De Marinis: Honoraria (self), Advisory/Consultancy: Roche, AstraZeneca; Advisory/Consultancy: Takeda; Research grant/Funding (self): Boehringer Ingelheim; Honoraria (institution), Research grant/Funding (self): Merck Sharp and Dohme.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.